Biostimulation is not simply “longer-lasting filler”
At Dr. Orhan Demirer’s dermatology practice in Alsancak, biostimulatory filler planning is CaHA-focused. A selected structural contour target is separated from a broader tissue-quality target, and the limits of a non-HA material are discussed before treatment.
- CaHA-specific assessment; PLLA is not offered at this practice
- Structural support separated from diluted skin-quality planning
- Product, treatment site and current local indication checked
- Non-reversibility, delayed reactions and vascular risk discussed clearly
What must be defined before CaHA is selected?
Which product class?
Plain CaHA is distinguished from HA, PLLA and hybrid HA-CaHA products.
Contour or skin quality?
Projection and support are not the same indication as broader tissue-quality treatment.
Is the area appropriate?
Thin, mobile, inflamed or high-risk anatomy may require another option or no filler.
What if a problem occurs?
CaHA cannot be treated as an HA filler that has a simple dissolving pathway.
What does “CaHA biostimulatory filler” mean?
Calcium hydroxylapatite (CaHA) filler contains small CaHA microspheres suspended in an absorbable carrier gel. Depending on the exact product, indication and placement, the carrier can contribute to an early contour effect while the microspheres provide a scaffold associated with a gradual tissue response.
“Stimulates collagen” does not guarantee tightening, a fixed amount of new collagen or the same result in every person. The response is influenced by the material, dilution, distribution, treatment site, tissue quality, age, health, previous procedures and follow-up interval.
This page is specifically about CaHA. Dr. Orhan Demirer does not offer PLLA treatment. A broad marketing label such as “collagen filler” should never replace the name and traceability of the actual product.
CaHA, HA, hybrid HA + CaHA filler, energy devices and surgery compared
The most appropriate pathway follows the dominant anatomical or tissue-quality problem. None is automatically “better” in every face.
| Option | Main role | Time course | Reversibility / limit |
|---|---|---|---|
| Plain CaHA filler | Selected structural support or a separately planned, more diluted tissue-quality approach | Early carrier-related effect plus gradual biological response | CaHA microspheres are not dissolved by hyaluronidase |
| Hyaluronic-acid filler | Temporary volume, contour or hydration depending on product and site | Contour often visible early; settling varies | Many HA products can be reduced with hyaluronidase, but not with perfect predictability |
| hybrid HA + CaHA filler | Hybrid cross-linked HA plus CaHA in one product | HA-related early effect and CaHA-related gradual response | Not fully reversible; hyaluronidase does not remove the CaHA component |
| Energy-based treatment | Selected laxity, texture, pigment, vessels or deeper tissue targets depending on device | Usually gradual and device-specific | Does not replace missing volume; thermal and pigment risks differ |
| Surgical assessment | Meaningful skin or tissue excess and structural repositioning | Different recovery and durability profile | More invasive; filler should not be used to camouflage every surgical indication |
No treatment is also a valid outcome when the expected benefit is small, the anatomy is unsuitable or the person does not accept the material’s limits.
Structural support and tissue-quality planning must not be mixed
Focused structural plan
The aim is selected contour, support or projection in appropriate anatomy. Product information, treatment site, layer and total material matter. This is not simply “collagen stimulation everywhere.”
- Defined anatomical target
- Measured, conservative contour goal
- Early appearance expected
- Natural movement and proportions preserved
Diluted skin-quality plan
The material may be distributed more broadly when tissue quality is the dominant concern. The goal is not focal projection. Dilution and some sites may be off-label depending on the product and jurisdiction.
- Broader tissue-quality target
- Gradual assessment over weeks
- Not a substitute for surgical tightening
- No guaranteed collagen quantity
Staged combination plan
Filler, laser, RF microneedling, HIFU or another procedure may be sequenced when separate targets coexist. Staging helps the clinician judge response and avoid treating treatment-related swelling as anatomy.
- One target per decision
- Inflammation and healing respected
- Results reviewed before adding volume
- Device and filler records retained
Three “biostimulatory” categories patients commonly confuse
CaHA microspheres in a carrier gel
This is the material pathway described on this page. Structural and more diluted plans remain different clinical uses.
Poly-L-lactic acid
PLLA is a separate injectable material with a different preparation, session pattern and adverse-event profile. It is not offered at this practice.
hybrid HA + CaHA filler
A hybrid product combines cross-linked HA and CaHA. It is not identical to plain CaHA and is not fully HA-reversible.
Which concerns may be assessed for CaHA?
The cards describe consultation directions, not automatic injection sites. The exact product’s current Türkiye information takes priority.
Selected facial support
Lower-face, jawline, chin or selected midface support may be assessed when anatomy and the product’s indication are appropriate.
Selected laxity or crepiness
A broader, non-projection plan may be discussed for suitable tissue. This is different from filling a focal deficit.
Only with product-specific support
Hand or body treatment is not inferred from facial use. Current labelling, skin thickness and alternatives are reviewed site by site.
Lips and direct tear trough
Plain CaHA is not presented at this practice as a routine direct lip or under-eye filler. Thin, mobile tissue needs a different material decision.
Neck, décolletage and some diluted applications may be off-label depending on product and country. US FDA approval is not the same as Türkiye authorisation; both the local label and individual consent must be checked rather than assumed.
Who may be considered—and when treatment may be postponed
Assessment may be relevant for
- A defined structural or tissue-quality concern that matches CaHA
- Skin and soft tissue able to support the proposed plan
- Realistic expectations of gradual, variable and non-surgical change
- Acceptance that CaHA has no simple enzyme reversal
- Willingness to stage treatment rather than chase immediate overcorrection
- Ability to maintain records, urgent contact and follow-up
Delay or another pathway may be needed
- Active infection, inflamed skin, open wound or dental infection
- Pregnancy or breastfeeding for an elective procedure
- Unknown previous filler, a new lump or unexplained swelling
- Strong bleeding tendency, relevant medicine or uncontrolled illness
- Thin or mobile area where CaHA is not a routine choice
- Expectation of guaranteed lifting, fixed duration or easy dissolving
Share medicines, supplements, allergies, autoimmune or inflammatory conditions, previous fillers, threads, surgery, dental work and energy-based treatments. Do not stop prescribed medicines on your own.
How is a CaHA treatment plan built?
Define the concern
Contour, support, skin quality, laxity or asymmetry is translated into a visible and realistic target.
Review the history
Health, medicines, allergies, dental plans, old fillers and previous device treatments are recorded.
Examine at rest and movement
Skin thickness, tissue mobility, volume, bone support and facial expression are assessed from several angles.
Choose the pathway
Plain CaHA, HA, hybrid HA + CaHA filler, an energy device, referral, observation or no treatment is considered.
Confirm product and site
Brand, lot, expiry, local indication, intended area and whether the use is on- or off-label are clarified.
Consent to limits and risk
Gradual response, asymmetry, non-reversibility, delayed reactions and vascular emergencies are discussed.
Treat conservatively
The plan follows the smallest useful intervention rather than a package based only on syringe count.
Document and review
Photographs and product records are retained; further treatment follows healing and observed response.
What may change after CaHA treatment?
This timeline is illustrative, not a promise. Structural and diluted plans do not have identical visible courses.
Redness, tenderness, entry marks, firmness, swelling and an early contour change may be visible.
Bruising and swelling can fluctuate. Early asymmetry should not automatically trigger more filler.
The carrier-related appearance settles while a gradual tissue response may become more evident.
Result, tissue behaviour and maintenance need are reassessed; there is no fixed duration for everyone.
Changes that may be assessed
- Selected contour or support in a structural plan
- Gradual change in selected tissue-quality concerns
- Subtle improvement that respects facial movement
- A staged result rather than maximum correction in one visit
What CaHA cannot guarantee
- A surgical lift or removal of significant skin excess
- An exact collagen quantity or identical response on both sides
- A fixed start date, fixed duration or permanent benefit
- No bruising, swelling, nodules or vascular complications
CaHA with HIFU, RF microneedling, laser or Endolift
Different procedures can address different tissue layers, but doing everything together is not automatically more effective. The sequence depends on diagnosis, heat, inflammation, swelling, filler location and the need to judge each response.
When laxity or skin quality is dominant, the device response may be assessed before adding any contour material.
Selected structural deficits may be treated first when that is the principal target and later energy will not compromise assessment.
Staging often gives clearer attribution of swelling, benefits and adverse reactions and protects follow-up quality.
Unknown filler should not be covered with new CaHA
A previous product may persist, migrate or produce delayed swelling beyond its advertised duration. Time passing does not identify what remains in the tissue.
Identify the material
Bring product stickers, dates, amounts, injection sites, previous dissolving details and earlier photographs when available.
Examine before adding
Firmness, nodules, redness, tenderness, migration, asymmetry or recurrent swelling needs diagnosis before top-up.
Observe, investigate or treat
Depending on the finding, records, ultrasound where relevant, medication, observation or another specialist pathway may precede any new filler.
Hyaluronidase may reduce an HA component but cannot confirm or remove CaHA, PLLA, silicone or every unknown material. “Dissolve everything first” is not a universal plan.
Do not massage, mould or heat the area without personal instructions
Aftercare depends on product, area, instrument and treatment concept. The treating physician’s written advice takes priority over general internet routines.
Contact the practice if pain, colour change, worsening swelling, redness, heat, discharge, fever, a new nodule or another unexpected symptom develops.
- Do not judge the result while swelling is evolving.
- Do not press or massage a firm area unless specifically advised.
- Keep entry points clean and avoid unclean tools or devices.
- Follow personal advice for exercise, alcohol, heat and skin products.
- Coordinate dental work and other facial procedures with the clinician.
- Keep urgent contact and emergency instructions readily available.
Common reactions, delayed problems and vascular emergencies
CaHA is absorbable, but that does not make it risk-free or easily reversible. Adverse effects can appear immediately or after weeks, months or longer.
More common and usually temporary
Swelling, redness, bruising, tenderness, firmness, itching, entry marks and early asymmetry may occur. Their duration varies with treatment area and scope.
Persistent or delayed problems
Infection, persistent irregularity, visible or palpable material, delayed inflammation, papules, nodules, granuloma, migration, ulceration and scarring may require assessment.
Possible blood-flow problem
Increasing or unusual pain, blanching, white-grey-blue mottling, coolness, delayed capillary refill, blisters or a worsening dusky area needs immediate contact and urgent assessment.
Vision or neurological symptoms
Sudden blurred, double or lost vision; eye pain; eyelid droop; severe headache; weakness or speech difficulty is an emergency requiring immediate medical care.
Safety and material distinctions were cross-checked against current FDA dermal-filler guidance, a systematic review of biostimulatory injectables and published CaHA consensus recommendations. Current Türkiye product information and local emergency pathways take priority.
CaHA is not an HA filler with a dissolving switch
Hyaluronidase breaks down hyaluronic acid. It does not dissolve CaHA microspheres. A result that is too prominent, asymmetric, irregular or inflamed therefore needs diagnosis-specific management rather than a promise of instant reversal.
Depending on the finding, management may include observation, medication, imaging, a targeted procedure or rarely surgery. A hybrid HA-CaHA product may have an HA component that responds to hyaluronidase, but its CaHA component remains; the whole treatment is not thereby “reversed.”
This limitation is one reason to define the indication conservatively, avoid inappropriate thin/mobile areas and keep exact product records.
When might another option fit better?
| Dominant concern | Possible assessment direction | Why CaHA may be limited |
|---|---|---|
| Precisely adjustable temporary volume | Appropriate HA filler or no filler | HA has different product options and a partial enzyme-management pathway |
| Thin or mobile lip / tear-trough tissue | Site-specific HA assessment, another method or no treatment | Plain CaHA is not a routine direct option at this practice |
| Hybrid early volume plus CaHA response | hybrid HA + CaHA filler assessment where indicated | It is a distinct product with its own limits and is not fully reversible |
| Skin texture, pigment or vessels | Diagnosis-specific laser, light, RF or medical skincare | Filler does not directly treat pigment, vessels or every surface problem |
| Meaningful laxity or tissue excess | Energy-device or specialist surgical assessment | Injectable volume cannot reproduce tissue removal or repositioning |
Biostimulatory filler prices in Izmir
Pricing depends on whether CaHA is appropriate, the selected traceable product, structural or tissue-quality goal, treatment area, material amount, complexity, combination planning and follow-up.
A generic syringe price does not show product authenticity, on- or off-label status, anatomical planning, asepsis, documentation, emergency readiness or review access. Some consultations correctly end without injection.
Describe the main concern, desired area, previous fillers and any laser, HIFU, RF, thread or surgical treatment.
CaHA planning with Dr. Orhan Demirer
Dr. Orhan Demirer is a specialist dermatologist practising in Alsancak, Izmir. He evaluates skin quality, facial support, movement, tissue thickness, previous filler and medical history before recommending a material.
The consultation may lead to a conservative structural CaHA plan, a separate tissue-quality plan, HA or hybrid HA + CaHA filler assessment, energy-based treatment, staged care, referral or no procedure. Dr. Orhan does not offer PLLA.
- Specialist dermatology assessment
- Plain CaHA separated from hybrid and HA fillers
- Traceable product, documented amount and follow-up
- English communication for international patients
Planning CaHA treatment in Izmir from abroad
Photographs help communicate a concern but cannot establish tissue thickness, mobility, previous filler or the safest material. Final indication and product choice are made in person.
Share preferred dates, medicines, allergies, health conditions and records of fillers, threads, dental work, lasers, RF, HIFU or surgery.
Structural and tissue-quality goals, alternatives, current product information, non-reversibility and urgent risks are discussed in English.
Allow for visible swelling or bruising, keep urgent contact information and agree how the settled response will be reviewed after departure.
Do not schedule an elective injectable immediately before a flight or onward travel that would prevent observation or urgent reassessment if pain, colour or vision changes occur.
Biostimulatory filler in Izmir: CaHA questions
What is a CaHA biostimulatory filler?
Calcium hydroxylapatite, or CaHA, is an absorbable filler material made of CaHA microspheres suspended in a carrier gel. Depending on the exact product and plan, it may provide early structural support while a gradual tissue response develops. This page describes CaHA rather than every product marketed as a biostimulator.
Is CaHA the same as hyaluronic-acid filler?
No. HA and CaHA are different materials with different tissue behaviour, approved indications and management options. HA is often selected for adjustable temporary volume; CaHA may be selected for structural support or a broader skin-quality plan when appropriate.
Is CaHA the same as hybrid HA + CaHA filler?
No. hybrid HA + CaHA filler is a hybrid product containing cross-linked hyaluronic acid and CaHA. A plain CaHA product and a hybrid HA-CaHA product should not be presented as interchangeable, and their product information, handling and reversibility limits differ.
Do you offer PLLA or Sculptra?
No. Dr. Orhan Demirer does not offer PLLA treatment. The biostimulatory-filler pathway described on this page is CaHA-focused; alternatives are discussed if CaHA does not match the indication.
Is the result immediate?
An early contour change may be visible because of the carrier gel, placement and temporary swelling. This is not the same as the gradual tissue response, which develops over weeks and varies between people. The treatment-day appearance is not a reliable final result.
When does the collagen-related change appear?
Biological remodelling is gradual rather than an overnight switch. Clinical change is assessed over the following weeks and months, but the timing and degree cannot be guaranteed from a product name alone.
How long does CaHA filler last?
There is no universal duration. Product, indication, amount, treatment area, tissue, metabolism and whether the plan is structural or more diluted all matter. Product-specific study averages are not a promise for an individual patient.
What is the difference between structural and diluted CaHA treatment?
A structural plan uses the material for selected contour or support targets. A diluted or more broadly distributed plan prioritises skin quality and tissue response rather than focal projection. These are different indications, and the latter may be off-label depending on the product, area and country.
Which areas can be assessed for CaHA?
Selected lower-face or midface support, jawline or tissue-quality concerns may be assessed. Hands or other sites are considered only when the exact product information supports them. The indication, layer and local regulatory status are checked for every area.
Is CaHA routinely used in the lips or under the eyes?
No. Dr. Orhan Demirer does not present direct lip or tear-trough CaHA injection as a routine option. These thin, mobile areas have different requirements, and another material or no filler may be more appropriate.
Can CaHA be dissolved with hyaluronidase?
No. Hyaluronidase acts on hyaluronic acid; it does not dissolve CaHA microspheres. A hybrid HA-CaHA product is also not fully reversible simply because its HA component may respond to hyaluronidase.
What happens if I dislike the result or develop a problem?
Management depends on the finding. Observation, medication, imaging, a targeted procedure or, rarely, surgery may be considered. Because CaHA does not have a simple enzyme reset, conservative indication and product records are especially important.
Is a cannula safer than a needle?
They are different instruments and neither removes vascular risk. Patient selection, anatomy, product, intended layer, technique, observation and emergency readiness all contribute to safety.
Can CaHA be combined with laser, HIFU or RF microneedling?
Sometimes, but the sequence is planned rather than stacked automatically. Heat, inflammation, swelling, tissue planes and the ability to assess each result affect timing. Energy treatment before filler may be preferable in some plans.
What are the common side effects?
Temporary swelling, bruising, redness, tenderness, firmness, entry marks and early asymmetry may occur. Persistent irregularity, infection, delayed inflammation, nodules, granuloma or migration require medical assessment.
Which symptoms need urgent medical attention?
Increasing or unusual pain, blanching, grey-blue mottling, cool skin, blistering or a worsening dusky area needs immediate assessment. Sudden visual change, eye pain, eyelid droop, severe headache, weakness or speech difficulty is an emergency.
Can I have CaHA during pregnancy or breastfeeding?
Dr. Orhan Demirer generally postpones elective CaHA treatment during pregnancy and breastfeeding because adequate safety evidence for cosmetic use is limited.
How much does biostimulatory filler cost in Izmir?
The fee depends on whether CaHA is appropriate, the selected traceable product, structural or skin-quality goal, treatment area, material amount, complexity and follow-up. A personal scope is discussed after examination rather than from a generic syringe package.
First decide: structure, tissue quality, another method—or no filler?
A responsible CaHA plan begins with the material, indication and exit-plan limits, not a package or a promise of guaranteed collagen.